Company CVAbout Jenburkt Pharmaceuticals Ltd. 
Jenburkt Pharmaceuticals Ltd.
Micro Cap
Pharmaceuticals & Biotechnology
Jenburkt Pharmaceuticals Ltd, incorporated in 1985, was formed a venture to diversify into the healthcare and pharmaceutical industry, by Bhuta family. The Company is engaged in manufacturing and marketing of speciality and high quality pharmaceutical formulations and healthcare products. Presently, the Company manufactures and markets pharmaceutical formulations in India and internationally across 13 countries.
Company Coordinates
Company Details
Nirmala Apartment P B No 37396, 93 Jayprakash Road Andheri(W) Mumbai Maharashtra : 400058
Registrar Details
Bigshare Services Pvt Ltd , E-2 , Ansa Industrial Estate, Saki Vihar Road, Saki Naka, Andheri (E), Mumbai
Capital StructureCapital Structure
Present Equity Capital
INR 4.41 Cr
Number of Shares
44.13 Cr
Face Value
INR 0.0
Date
Number
of Shares(Cr)
of Shares(Cr)
Equity
Capital (Rs Cr)
Capital (Rs Cr)
Shares Added
Face Value (Rs)
Reason
29-Mar-2023
44.13
4.41
-176078
0
Buy Back of Shares
ShareholdingShareholding Snapshot
Shareholding Compare (%holding)
Majority shareholders
Non Institution
Pledged Promoter Holdings
None
Mutual Funds
Held by 0 Schemes
FIIs
Held by 0 FIIs
Promoter with highest holding
Ashish Uttam Bhuta (18.07%)
Highest Public shareholder
Nirmala Vinodkumar Daga (3.3%)
Individual Investors Holdings
43.26%
Board of Directors
Management
Designation
Remuneration
Bharat V Bhate
Non-Exec. & Independent Dir.
1.25 lacs
Rameshchandra J Vora
Non-Exec. & Independent Dir.
1.25 lacs
Arun R Raskapurwala
Non-Exec. & Independent Dir.
1.25 lacs
Ashish R Shah
Company Sec. & Compli. Officer
0
Ashish U Bhuta
Chairman & Managing Director
2.01 cr
Dilip H Bhuta
Whole Time Director & CFO
60.37 lacs
Hina Ravindra Mehta
Non-Exec. & Independent Dir.
1.25 lacs
Sumit Ajaybhai Thakkar
Independent Director
0
Raw MaterialsRaw Materials Dashboard
Raw Materials
Amount(Rs Cr)
% of RM Cost
No Data Available for Raw Material Segmentation
No Data Available
Finished Goods Finished Goods Dashboard
Finished Goods
Amount(Rs Cr)
% of Sales Turnover
Pharmaceuticals Formulation
122.05
99.52%
Other Operating Revenues
0.59
0.48%
Pharmaceuticals Formulation
Pharmaceuticals Formulation
Other Operating Revenues
Other Operating Revenues
Stock DNARevenue and Profits:
Net Sales:
46 Cr
(Quarterly Results - Sep 2025)
Net Profit:
10 Cr
Pharmaceuticals & Biotechnology
INR 498 Cr (Micro Cap)
15.00
27
0.00%
-0.04
18.04%
2.76
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
